Publication date: Jul 15, 2025
While dexamethasone has been shown to improve survival in COVID-19, its dose-response relationship with plasma glucose (PG) levels and insulin requirements is poorly understood. This study investigated the impact of 12 mg (higher dose) versus 6 mg (standard dose) of dexamethasone on hyper- or hypoglycemic events and the use of insulin. A secondary analysis of a subpopulation of the COVID STEROID 2 trial. Glycemic outcomes were assessed by time-to-event analysis of a hyperglycemic (two PG measurements ≥ 11. 1 mmol/L), severe hyperglycemic (PG > 20 mmol/L), hypoglycemic (
| Concepts | Keywords |
|---|---|
| Covid | Adverse events |
| Insulin | COVID-19 |
| Measurements11 | COVID-steroid 2 trial |
| Severe | Dexamethasone treatment |
| Steroid | Hyperglycemia |
| Hypoglycemia | |
| Insulin | |
| Secondary analysis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Hyperglycemia |
| disease | MESH | COVID-19 |
| disease | MESH | hypoxemia |
| drug | DRUGBANK | Dexamethasone |
| drug | DRUGBANK | Dextrose unspecified form |
| disease | MESH | Hypoglycemia |
Original Article
(Visited 2 times, 1 visits today)